Abbott Laboratories agrees to a $385 million settlement related to the closure of what is described as the largest baby formula plant in the United States. The closure occurred in the period leading up to the 2022 baby formula shortages, and sources say the shutdown contributed to supply problems reported across the country.
Both outlets frame the agreement as resolving claims connected to the plant’s closure and the resulting disruption in formula availability. The reports do not add significantly differing details about the underlying allegations beyond the link to the 2022 shortages, and they do not specify timelines for when the settlement is finalized or how funds are allocated. The key common point is the settlement amount and the causal connection drawn between the plant’s closure and the widespread shortages experienced in 2022.
Overall, the coverage centers on the settlement figure and the closure–shortage relationship, with limited additional information in the provided summaries about the legal basis or specific terms.
